Summary The anti-tumour actvity of methyl-p-cyckxdextrin (MEBCD), a cydic oligosaccharide known for its interaction with the plasma membrane, was investigated in vitro and in vivo and compared with that of doxorubicin (DOX) in the human tumour models MCF7 breast carcinoma and A2780 ovanan carcinoma. In vitro proliferation was assessed using the MTT assay. In vivo studies were carmied out using xenografted Swiss nude mice injected weeldy i.p. with MEBCD at 300 or 800 mg kg-, or DOX at 2 mg kg-', durng 2 months. Undrer these conditions, MEBCD was active against MCF7 and A2780 cell lines and tumour xenografts. For each tumour model, the tumoral volume of the xenografted mice treated with MEBCD was at least twofold reduced compared wit the control group. In the MCF7 model, MEBCD (800 mg kg-') was more active than DOX (2 mg kg-1). After 56 days of treatnent with MEBCD, no toxicologically meaningful differences were observed in macroscopic and microscopic parameters compared with controls. The accumulation of MEBCD in normal and tumour tssues was also assessed using a chromatographic method. Results indicated that after a single injection of MEBCD, tumour, liver and kidneys accumulated the highest concentrations of MEBCD. These results provided a basis for the potental therapeutic application of MEBCD in cancer therapy.
Toxicitv and drug resistance are probably the major mechanisms for failure of therapy in cancer. To oxvercome these problems. there is a need to develop antiproliferatiVe agents actix e on other cellular targets. such as the cell membrane.
Cvclodextrins (CDs) are known for modifying, the physicopharmaceutical properties of various drugs and components through inclusion complex formation (-Hiravama and Uekama. 1987: Allegre and Deratani. 1994 : Bressolle et al. 1996) . The inclusion of the drug may have several advantages. such as an increased aqueous solubilitx and stabilitv or a reduction of unwanted side effects (Szetlji. 1994 ). However. CDs should not be regarded as simple excipients or solubility enhancers because the formation of inclusion complexes might occur with some biological components such as cholesterol and lipid components of the biological and cellular membrane. leading to an enhanced permeability to various molecules (Cho et al. 1995 : Hovgaard and Brondsted. 1995 : Krishnamoorthy et al. 1995 . Thus. we have previously shown that. at non-cvtotoxic concentrations. methyl-[-Bcyclodextrin (MEBCD) was able to potentiate the in vitro anti-tumoral actix itv of doxorubicin (DOX) in several parental sensitix e cancer cell lines and their multidrug-resistant sublines. but x-e also showed that the action of MEBCD on the cell was independent of that of DOX (Grosse et al. 1997a (Grosse et al. . 1998 . Several studies confirm that some CDs have their own cellular activiity in terms of interaction with the plasma membrane. permeabilization or haemolytic activitv (Szejtli et al. 1986 : Castelli et al. 1989 ; Kilsdonk et al. 1995) . Only a fexx in vivo studies concerning the effect and the toxicitx-of CDs injected directlx in human or animal organisms hax-e been performed. x-hereas there are no reports on the use of CDs in cancer (Bellrinner et al. 1995) . The toxicolooical effects appeared to be related to the structure of the CD. Non-substituted CDs were found to be highly toxic for the kidneys (Brexster et al. 1990 : Bellringer et al. 1995 . whereas the toxicitv of substituted CDs varies with the degree and the nature of the substitution (Frijlink et al. 1990 . 1991 : Giordano. 1991 : Flourie et al. 1993 
MEBCD sensitivity in vitro
The human breast adenocarcinoma cell line MCF7 (Soule et al. 1973 : Minnaugh et al. 1991 (Alley et al, 1988; Heo et al, 1990; Colangelo et al, 1992) . Metabolic reduction of the tetrazolium salt MTI [3-(4,5-dimethylthiazol-2yl Detemination of MEBCD LD.0 in mice MEBCD LD 5 was determined using female Swiss mice aged S weeks and weighing 22-28 g. Seven groups of six mice (MEBCD at 100, 200, 500, 1000, 1500, 2000 and 3000mg kg-') were injected i.p. weekly for 4 weeks and were then monitored over a span of 2 months.
MEBCD sensitivity in vivo
MCF7 and A2780 cells diluted in RPMI-1640 medium (107 cells in 250 1) were inoculated subcutaneously into the flank area of female nude congenic athymic mice of Swiss strains homozygous for the nude gene (nu+/nu+). All mice were purchased from Iffa Credo (Lyon, France). They were aged 5 weeks and weighed 20-22 g at the start of experiments. These were conducted in accordance with the protocols published by the European Organization for Research and Treatment of Cancer (EORTC) members (Geran et al, 1972) . Mice were kept under sterile conditions and were given sterilized food and water. As the MCF7 human cancer cell line requires exogenous oestrogen for efficient tumorigenicity, the mice intended for MCF7 xenografts were, therefore, aseptically implanted subcutaneously in the intrascapular region with 0.72 mg 60-day release 17.oestradiol pellets (Innovative Reseach of America, Toledo. OH, USA) 2 days before injection of tumour cells. The A2780 tumour cell line is oestrogen independent and does not respond to oestradiol stimulation of proliferation in vivo. The growth of MCF7 and A2780 xenografted tumour was monitored every 7 days by measuring the tumour with calipers in three dimensions following the formula length x width x thickness x m16 as described for murine solid tumours (Tomayko and Reynolds, 1989 
MEBCD tumoral and tissular distribution
To determine the relative concentrations of MEBCD in MCF7 and A2780 xenografted mice and to contrast tumour drug levels with host tissues, MEBCD at 800 mg kg-' was administered i.p. to mice. Three hours later, the animals were killed by cervical dislocation and tumours, liver, kidneys, lungs, small intestine and brain were removed, washed in PBS, weighed and frozen for later processing. After thawing, tumours and tissues (0.5 g) were quartered and homogenized in 1 ml of purified water with a Tissue Tearor homogenizer (Biospec Products, Bartlesville, OK, USA). Samples were then treated as described in a previous paper (Grosse et al, 1997b) . Briefly, after addition of 20 p1 of potassium hydroxide (5 M), alkaline extraction of MEBCD was carried out using 3 ml of chloroform. The lower organic phase was transferred to a fresh tube and evaporated under nitrogen stream. The residue was then reconstituted into 200 1 of mobile phase consisting of a mixture of water and methanol (98:2 v/v) containing 10-4 M of 1-naphthol as a fluorophore and injected onto the analytical column. The detection of MEBCD is based on the enhancement of fluorescence of l-naphthol caused by its complexation in the cavity of the CD. The flow rate was 1 ml min-'. A stainless-steel column (300 x 7.5 mm i.dc) packed with exclusion gel TSK 3000 SW was used and fluorimetric detection was performed at excitation and emission wavelengths of 290 and 360 nm respectively. Experiments were carried out in triplicate.
Statistical analysis
In each treated group. data were analysed by ANOVA one-way tests (compared with control values) and differences between mean values at P < 0.05 were considered to be significant. Figure 3A . Experiments on the four groups of six mice were carried out in duplicate and show. after 5 weeks of treatment. a clear reduction of the tumour x-olume in mice receix ing MEBCD at 300 or 800 mg kg-1. compared with control. The antiproliferative activity of MEBCD was statistically higher than the DOX one. To confirm these data in a non-oestrogen-dependent tumour model. actixity of some antineoplastic agents induce( with non-cytotoxic concentrations of MEBCI cell lines (Grosse et al. 1997a (Grosse et al. . 1998 M). The proliferation 1990 : Frijlink et al. 1991 : Giordano. 1991 ). As 0.5 ml of plasma is at MEBCD concenrequired for the HPLC method. MEBCD plasma levels were not ition of growth was determined in mice. In contrast. the tropism of MEBCD for the um. To confirm this xenografted tumour is proven by its tumoral accumulation. which inoculated with the is undoubtedly linked to the tumour growth inhibition observed.
MCF7 model and
This antiproliferative activity should be due to the great affinity ormal saline. After 5 of MEBCD for cell membrane lipid components. particularly eated with MEBCD cholesterol. which play a major role in the structure and the funciced compared with tioning of the cell membrane. Thus. MEBCD is able to include ivertook 50% of the cholesterol in its cavity and then to remove it from the cell -emarkable aspect is membranes (Castelli et al. 1989 : Szejtli et al. 1986 800 mg kg'l) was at 1995: Hovgaard and Brondsted. 1995: Kilsdonk et al. 1995: mtineoplastic agent Krishnamoorthy et al. 1995) .
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Plasmatic and tissular pharmacokinetics of MEBCD and DOX. alone or in combination, are actually being performed in rabbit to gather further knowledge on biological comportment of MEBCD. Moreover, assays will be carried out to investigate the antiproliferative activity of MEBCD in cell lines and xenograft tumour models overexpressing the MDR phenotype.
The cytotoxicity against two human carcinoma cell lines, the inhibition of MCF7 and A2780 xenografted tumour growth comparable to that obtained with DOX, and the apparent innocuity of doses injected in xenografted nude mice make of MEBCD. alone or in combination with other antineoplastic agents, a potential candidate for cancer therapy.
